Managing HIV Drug ResistanceFeatures

DAWNING Study Casts New Light on the Details of Resistance

#7 in TheBodyPro's Top 10 HIV Clinical Developments of 2019

The DAWNING Study photo illo
Photo illustration: Remedy Health Media; Background and paper tear: iStock
    • First presentation of DAWNING results: 9th IAS Conference on HIV Science. (2017). "Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study."
    • First published DAWNING results: Lancet Infectious Diseases. (2019). "Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open- label, non-inferiority, phase 3b trial."
    • DAWNING baseline resistance data: CROI 2019. (2019). "DTG vs LPV/r (DAWNING): Efficacy by Baseline NRTI Resistance and Second-Line NRTI Use."
    • FLAMINGO study: The Lancet. "Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study."
    • Italian switch study: Antiviral Research. (2019). "No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference."
    David Alain Wohl, M.D.

    David Alain Wohl, M.D.

    David Alain Wohl, M.D., is a professor at the University of North Carolina, site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AETC, and co-director of HIV services for the NC state prison system.